Chemoprevention of breast cancer by tamoxifen: Risks and opportunities

Critical Reviews in Toxicology

Volumn 30, Issue 5, 2000, Pages 571-594

  Smith, L L ^a   Brown, K ^a   Carthew, P ^a   Lim, C K ^a   Martin, E A ^a   Styles, J ^a   White, I N H ^a  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

32P postlabeling; Accelerator mass spectrometry; Active metabolites; DNA damage; Liver tumors; Tamoxifen

Indexed keywords

CYTOCHROME P450 3A; DNA; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; DNA DAMAGE; ENDOMETRIUM CARCINOMA; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; RAT; REVIEW;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0033809955     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408440008951120     Document Type: Review

References (136)

1. Tamoxifen - The treatment of choice. Why look for alternatives?
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women
3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
4. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
5. Drugs for osteoporosis prevention: Mechanisms of bone maintenance
6. 8-cholestenol conversion to lathosterol in women with breast cancer
7. BRCA1 and BRCA2: From molecular genetics to clinical medicine
8. The case for clinical trials of tamoxifen for prevention of breast cancer
9. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
10. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
11. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
12. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women
13. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
14. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group
15. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
16. Second cancers after adjuvant tamoxifen therapy for breast cancer
17. Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats
18. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat
19. Tamoxifen induces hepatocellular carcinoma in rat liver - A 1-year study with 2 antiestrogens
20. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital
21. Induction and promotion of gamma - Glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations
22. Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats
23. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumor formation
24. The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen
25. Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Cr1: CD(BR) rats
26. Initiating activity of the antiestrogen tamoxifen, but not toremifene in rat liver
27. Depletion of hepatocyte nuclear estrogen receptor expression is associated with promotion of tamoxifen induced GST-P foci to tumours in rat liver
28. Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver
29. A tumorspecific truncated estrogen receptor slice variant enhances estrogen-stimulated gene expression
30. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
31. Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent
32. Unlike tamoxifen, droloxifene produces no hepatic tumors in the rat
33. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
34. Tamoxifen
35. Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen
36. Uterine carcinoma in mice treated neonatally with tamoxifen
37. Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen
38. Tamoxifen-associated uterine pathology in rodents: Relevance to women
39. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia
40. Induction of covalent DNA adducts in rodents by tamoxifen
41. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells
42. 32P-post-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method
43. Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol
44. Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver
45. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite
46. DNA adduct-formation by tamoxifen and structurally related compounds in rat liver
47. Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: Comparison with DNA adducts formed in the uterus of Sprague- Dawley rats treated with tamoxifen
48. 14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry
49. Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat and mouse hepatocytes
50. The metabolic activation of tamoxifen and alphahydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulfation
51. Tamoxifen-induced DNA adducts in leukocytes of breast cancer patients
52. Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients
53. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro
54. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems
55. Activation of the tamoxifen derivative metabolite E to form DNA adducts: Comparison with the adducts formed by microsomal activation of tamoxifen
56. Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo
57. Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts
58. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen
59. Lack of genotoxicity of tamoxifen in human endometrium
60. A lack of evidence for the genotoxicity of tamoxifen and toremifene in the human endometrium
61. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients
62. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen
63. Cytogenic effects of a novel antiestrogen toremifene FC-1157a: A comparison with diethylstilbestrol and tamoxifen
64. Studies on the mutagenicity of tamoxifen
65. Factors influencing mutation at the hprt locus in T-lymphocytes: Women treated for breast cancer
66. Mutational spectra of tamoxifen-induced mutations in the livers of lacI transgenic rats
67. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats
68. Studies on tamoxifen-induced mutations in the liver and uteri of Big Blue(TM) transgenic F344 rats
69. Phenobarbital promotion does not influence the frequency of tamoxifen-induced mutations in the livers of Big Blue transgenic F344 rats
70. Site-specific tamoxifen-DNA adduct formation: Lack of correlation with mutational ability in Escherichia coli
71. Mutagenic potential of alpha-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen
72. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifem
73. Mutational hot spot in the p53 gene in human hepatocellular carcinomas
74. G to T mutations of p53 gene in hepatocellular carcinomas from Southern Africa
75. Tamoxifen has a characteristic mutation spectrum in human endometrial cancers
76. Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma
77. Micronucleus assays using cytochalasin-blocked MCL-5 cells, a proprietary human cell line expressing five human cytochromes P-450 and microsomal epoxide hydrolase
78. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s
79. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells)
80. Karyotypic changes in a multistage model of chemical hepatocarcinogenesis in the rat
81. Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats
82. Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats
83. Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene-type antiestrogens
84. Pharmacology of tamoxifen in laboratory animals
85. The metabolism of Tamoxifen *(I.C.I.46476).I. In laboratory animals
86. Metabolism of tamoxifen (I.C.I.46474). II. In female patients
87. Metabolism of tamoxifen and its uterotrophic activity
88. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment
89. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen
90. Analysis of tamoxifen and its metabolites by on-line capillary electrophoresis - Electrospray ionization mass spectrometry employing nonaqueous media containing surfactants
91. Analysis of phase 1 and phase 11 metabolites of tamoxifen in breast cancer patients
92. Identification of tamoxifen metabolites in human HEP G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer
93. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers
94. Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women
95. The pharmacology and clinical uses of tamoxifen
96. Age-related difference in tamoxifen disposition
97. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment
98. Measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumours
99. Metabolism of tamoxifen by rat liver microsomes: Formation of the oxide, a new metabolite
100. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes
101. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes
102. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation
103. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation
104. Delineation of human cytochromes P450 involved in the metabolism of tamoxifen
105. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved
106. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes
107. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver
108. Induction of CYP2B1 and 3A1 and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice
109. Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression
110. Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver
111. Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient
112. Peroxidase activation of 4-hydroxytamoxifen to free radicals detected by EPR spectroscopy
113. Cytochrome P450 mediated action and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: Possible involvement of the flavin-containing monooxygenases in tamoxifen activation
114. Identification of estrogenic tamoxifen metabolite(s) in tamoxifenresistant human breast tumors
115. On-line high-performance liquid chromatographic-electrospray ionization mass spectrometric method for the study of tamoxifen metabolism
116. 4-hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis
117. Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins
118. DNA-adducts formed by 3,4-dihydroxytamoxifen, a potential reactive metabolite of tamoxifen
119. Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone
120. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides
121. Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: Identification and quantification in vivo and in vitro
122. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism
123. The deuterium isotope effect for the α-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl]tamoxifen
124. α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA binding activity in rat hepatocytes
125. Rat but not human sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture
126. Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts
127. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen
128. Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen
129. DNA adducts of chemical carcinogens
130. 6 atom of adenine residues as sites for covalent binding of metabolically activated 1'-hydroxysafrole to mouse liver DNA in vivo
131. Minor products of reaction of DNA with a-acetoxytamoxifen
132. Identification of the major tamoxifen-DNA adduct in rat liver by mass spectrometry
133. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
134. Glucuronylation of alpha-hydroxytamoxifen: A deactivation pathway in humans?